Advances in Pediatric Cancer Research

Accreditation Statement 
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement
AACR has designated this live activity for a maximum of 19.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Claiming CME Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s) for this live continuing medical education activity must complete the CME Request for Credit Survey by Friday, Nov. 1, 2019. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on this website and via email. Your CME certificate will be sent to you via email after the completion of the activity.

Statement of Educational Need, Target Audience, and Learning Objectives
Cancer is the leading cause of death by a disease in U.S. children. An estimated 11,060 new cases of cancer will be diagnosed in children (up to 14 years old) in 2019. The majority of cancer therapies available are generally developed for adults and their efficacy in treating childhood cancers is unknown. From 1948 to 2003, regulators approved 120 new cancer therapies. However, only 15 contained information about pediatric use. Passage of the Creating Hope Act in 2016 catalyzed a renewed interest in developing treatments for children with cancer. Thus with the development of new therapeutic approaches specific to the treatment of childhood cancers, there is an urgent need to educate physicians and investigators on the newest approaches available based on recent research.

Pediatric cancers differ significantly from adult cancers. For example, childhood cancers are found in different areas of the body than adult cancers. Leukemias and brain and other central nervous system tumors comprise the major types of childhood cancers and account for more than half of new cases. Survival rates for childhood cancers vary depending on the type of cancer and other factors. Additionally, most childhood cancers cannot be prevented, and the precise cause of most childhood cancers is unknown. Unlike adult cancers, childhood cancers are not strongly linked to environmental or lifestyle risk factors but depend more on genetic factors. Thus, given the dependence on genetic factors for most childhood cancers, the ability to translate recent advances in genomics and epigenomics into clinical practice and apply them to generate effective treatments is key to combatting childhood cancers. Additionally, immune therapy approaches and therapies targeting biologic drivers are important. The central role of translational research and clinical trials is highlighted by the fact that declines in the mortality rate from a number of childhood cancers can be attributed to improved treatments and a high proportion of participation in clinical trials. This conference will bring together top basic, translational, and clinical researchers in the field to discuss recent findings in genomics/epigenomics, developmental biology, immune therapies, and cellular mechanisms and how these translate into new therapeutic approaches for childhood cancers. The conference will also address the opportunities and challenges in pediatric oncology translational science and clinical trials.

To combat pediatric cancers, there is a need to educate physicians on the role of the various factors involved in the development of childhood cancers and how basic research findings can be translated effectively to the clinic to develop new therapeutic approaches. This conference will bring together a wide range of physicians, scientists, health professionals, and health care leaders to discuss the latest findings in their fields, to foster collaborative interdisciplinary interactions and partnerships, and to stimulate the development of new research and clinical practices.

After participating in this CME activity, physicians should be able to:

  1.  Articulate how to apply genomics data to identify therapeutic targets for pediatric cancers

  2. Compare various precision oncology approaches for childhood cancer patients

  3. Evaluate immune-based therapies for childhood cancer

  4. Describe approaches to identify cancer predisposition and strategies for surveillance in pediatric cancer

  5. Assess the utility of targeted therapies for pediatric cancers

  6. Explain recent findings on survivorship in those treated for pediatric cancers

Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.

Acknowledgement of Finanicial or Other Support
This activity is supported by independent medical educational grants and will be disclosed at the activity.

Questions about CME?
Please contact the Office of CME at (215) 440-9300 or

Top of page